Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CCKAR | P32238 | 2/20 | 0.58 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.57 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | CCKBR | P32239 | 1/20 | 0.54 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701154 | 0.85 | NHERF1 (0.74) | NPC1LMNARAB9ASMN1; SMN2CCKAR | |
| SCHEMBL1310023 | 0.84 | NHERF1 (0.73) | NHERF1 | |
| SCHEMBL6834022 | 0.82 | NPC1 (0.55) | NPC1LMNARAB9ASMN1; SMN2CCKAR | |
| SCHEMBL1308155 | 0.81 | NPC1 (0.58) | NPC1LMNARAB9ASMN1; SMN2CCKAR | |
| SCHEMBL5950457 | 0.81 | GRIK1 (0.65) | NPC1LMNARAB9ASMN1; SMN2AKR1C4 | |
| SCHEMBL9513479 | 0.80 | MAPT (0.80) | AKR1C4AKR1C3AKR1C2AKR1C1MAPT | |
| SCHEMBL17433428 | 0.79 | NPC1 (0.78) | NPC1LMNARAB9ASMN1; SMN2PIN1 | |
| SCHEMBL6833115 | 0.78 | AKR1C2 (0.49) | NHERF1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1306446 | 0.78 | NHERF1 (0.74) | NPC1LMNARAB9ASMN1; SMN2CCKAR | |
| SCHEMBL21446808 | 0.76 | CCKAR (0.66) | NPC1LMNARAB9ASMN1; SMN2CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | NPC1 3431/4885LMNA 1387/4885RAB9A 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.